Skip to Main Content

Paper Details

Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
J Prev Alzheimers Dis
3
2019

Datasets

Release 1.2